The major problem facing world research for new antimalarials lies in encountered difficulties in the search for new promising paths. The past 20 years have witnessed a very impressive increase in our understanding of the biochemistry and molecular biology of malaria parasites, with attention focused on specific parasite molecules that are keys to the parasite life cycle or the induction of its pathogenesis. Directed pharmacology research has involved the identification and characterization of targets that can be specifically pharmacologically affected, including the replicating machinery of the parasites, various metabolisms such as the purine salvage pathway, and biosynthesis of pyrimidines or phospholipids. Protease inhibitors (e.g. those degrading haemoglobin], the use of iron chelators or inhibition of heme polymerization, induction of oxidative stress or inhibition of antioxidant enzymes are also investigated. Some pathways have already been validated with current antimalarials but, due to the development of resistance, complete characterization of the molecular structure of the target should allow attack of these exceptional molecules at novel and distinct sites with new drug concepts. The problem in the quest to develop new antimalarials is the fact that the results are not being materialized, but there is no lack of pharmacological targets.
INTRODUCTION
V iewed globally, parasitic diseases pose an increasing threat to human health and welfare.
In the last 25 years, malaria has regained its former position as the greatest threat to the health and economic prosperity of mankind. The rising costs of insecticides, the development of resistance to organochlorines, such as DTT, and the spreading resistance of PLASMODIUM FALCIPARUM to most available drugs can be held responsible for this depressing picture. The development of a vaccine against malaria has so far not fulfilled expectations in field trials (Maurice, 1995;  Tanner ET line antimalarial drugs would be of great practical interest, but no compounds have yet proven effective at therapeutic doses.
PHARMACOLOGICAL STRATEGY
Several natural products isolated from plants used in traditional medicine have potent antiplasmodial action in vitro and represent potential sources of new antimalarial drugs. The clinical efficacy of artemisinin demonstrates that quinine is not the sole antimalarial drug obtainable from the plant kingdom. Nevertheless, these points will not be discussed below. Many other plant constituents have antimalarial activi ties and could give rise to new antimalarial drug concepts (Phillipson, 1994) . There are often difficulties in synthesizing de novo the drugs on a commercial scale, and improving the activity through hemisynthetic compounds. Moreover, in a number of cases, there is cross-resistance with currently used antimalarials. A necessary first step is to identify a molecular target critical to the disease process; infectious pathogens are particularly suited for the exploitation of divergent or completely novel metabolic pathways. The pharma cological target must be implicated in the life cycle of the infectious agent, in its pathogenesis or virulence. Identifying these molecules and determining their exact functions require fundamental research on the infec tious agents with respect to their internal biochemistry, interactions with their hosts, and pathological orga nisms. Another step is to determine how crucial the target molecule is for the pathogenic agent or the pathological process. This is of utmost importance since the ensuing exercise work is very time and money-consuming.
Secondly, pharmacology is synonymous with selecti vity, and hence requires identification of biochemical processes that could be selectively disrupted by utili zing differences between host and parasite proteins for designing drugs. Most of the enzymes have become well adapted to regulate specific metabolic needs of the malaria parasite during its asexual or sexual stages. Drugs are usually directed at residues that are essen tial for parasitic functions, such as substrate-binding site residues of enzymes. Unfortunately, most amino acid residues implicated in substrate and coenzyme binding and catalysis are often found to be highly conserved. It is therefore necessary to identify rare and unique regions in the protein sequences. Amino acid insertions and deletions are often observed allowing a detailed understanding of unique features of the active site for this complex life cycle of malaria parasites. The next step is, if possible, full characterization of the molecular structure of the target. A number of plas-
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Mise au point Parasite, 1996, 3, 3-23 cipanun malaria since parasitemia goes up until the host's death and whose feared complication is cere bral malaria. The nonerythrocytic stages of malaria parasites, including sporozoites, exoerythrocytic liver stages, sexual gametocyte stages and all mosquito stages, are difficult to study and specific information regarding these stages is still scarce.
CURRENT ANTIMALARIAL DRUGS
O nly asexual erythrocytic parasites produce cli nical illness. Neither persistent exoerythro cytic hepatic parasites (hypnozoites) nor sexual parasites (gametocytes) produce recognizable clinical symptoms. Antimalarial agents that inhibit the replication of asexual erythrocytic parasites thus pro vide the most rapid clinical improvement. The oldest recognized antimalarial agent (quinine), the antimala rial agents used in World II (chloroquine and quinacrine), and newer agents used for chloroquine resis tant P. falciparum (mefloquine and halofantrine), have amino-substituted or methanolic substituted multiring structures. Two other structural classes, dihydrofolate reductase (e.g. pyrimethamine), and p-aminobenzoic analogues (e.g. sulfadoxine) are used in combination. Other important drugs include inhibitors of protein syn thesis (e.g. tetracycline and doxycycline). Although toxic side effects are a major drawback in its use, the 8-aminoquinoline primaquine, which was introduced in 1952, is used to treat the other parasite stages (exoerythrocytic and sexual erythrocytic parasites) and remains the most effective agent for the radical cure of P. vivax malaria (Wemdorfer et al, 1991; White, 1992) .
The increasing capacity of malaria parasites to resist chemotherapy causes a frightening deterioration in the efficacy of conventional antimalarial drugs. Resis tance concerns the two main series of blood schizonticicles, lysosomotropic agents and the antifol combi nation group with a rapid worldwide spread (Werndorfer & Payne, 1991 ) . Indeed, malaria patho gens are highly adaptable to chemical changes in their environment. Following introduction of a new drug, it can be anticipated that P. falciparum will develop resistance within a few years. At present time, there is no agent that can offer protection against malaria in all regions of the world; the need for novel chemotherapeutic agents is therefore acute. Drugs now being developed include artemisinin derivatives, pyronaridine (both originally developed in China), new antifolate combinations, atovaquone and a new 8-aminoquino line. Some of these drugs may become available within the next few years . Resistance modifiers that restore the effectiveness of present first modial molecules have been purified, but their cha racterization has been hampered by the very low quantities available, inviting approaches using mole cular cloning techniques. Gene cloning combined with the expression of engineered genes encoding P. FAL CIPARUM proteins permit more detailed structure func tion studies of parasite proteins and could potentially help in developing specific antimalarial drugs. The structures of fewer than 1 % of the proteins have been characterized by X-ray crystallography or multidimen sional NMR spectroscopy. DE NOVO prediction of pro tein structures based on primary sequences is still insufficiently accurate and will require conceptual advances in the understanding at protein folding.
Homology-based modeling is an attractive approach that circumvents the absence of empirical structural data, as reasonable assumptions are made regarding structural conservation. Another advantage of this approach is the relatively high structural conservation in the immediate vicinity of the active sites of homo logous enzymes, but this is also a disadvantage since this part of the enzyme is often the target of pharma cological agents.
With an experimental or hypothetical structure in hand, the challenge is to find a complementary structure that can be translated into a good ligand or antagonist. The ultimate objective is to generate novel structures as potential lead compounds . It would be ideal to develop drugs with high affinity and selec tivity, and these agents could lie administered in about stoechiometric amounts relative to their ligands. The law of mass action dictates interaction of reversibly bin ding inhibitors. It follows that the free drug concen tration must be at 100-fold the K diss to inhibit the target greater than 99 % the target. Drug designs should focus on inhibitors with a K diss of less than 10" 8 M, otherwise the drug concentration must be very high to sustain the inactive complex, which could lead to an unacceptable dosage regimen (Schirmer ET AL., 1995) . Affinity of the ligand for the target involves numerous negative and positive interactions; the GibbsHelmholtz equation gives the free energy of ligand bin ding to macromolecules (Andrews, 1986; Schirmer ET AL., 1995) . The free energy change, AG associated with a drug receptor, is related to the equilibrium constant K for the interaction as set out by the equa tion: AG = -2.303 RT log K. Increasing the affinity of the ligand for the target usually requires reinforcement of the interactions through ionic, hydrogen and van der Waals bonds (Andrews, 1986) , in order to generate compounds of sufficient potency to serve as leads in new drug development.
NUCLEIC ACID SYNTHESIS
M alaria parasites require purine and pyrimidine for DNA and RNA synthesis. Targeting at this level is extremely harmful since it is particularly crucial for the life transmission in every organisms. However, specific plasmodial requirements have already led to the development of invaluable anti malarial drugs. Further characterization of the whole system will probably provide other selective targets in the future.
DNA REPLICATION
One such target could be the DNA synthesis rate limi ting enzyme ribonucleotide reductase (EC 1.17.4.1; RNR) that maintains in an allosterically controlled way, a continuous balanced supply of 2'-deoxyribonucleotides dNTPs for replication and repair of DNA by the reduction of ribonucleotides (Smeijsters ET AL., 1994) . RNR are heterodimeric enzymes with an α2β2 confi guration, and containing ferric ion which is essential for their activity. cDNA encoding both the large (pfR,) and small (pfR 2 ) RNR subunits of P. FALCIPARUM were recently cloned simultaneously by two groups (Chakrabarti ET AL., 1993; Rubin ET AL., 1993) . In contrast to mammalian ribonucleotide reductase, pfRl and pfR2 genes are located on the same chromosome. The large subunits were found to have 67 % of identity with human large subunits. The small regulatory subunit that contains the major catalytic motif consisting of a tyrosyl radical and a dinuclear Fe site, shares 59 % amino acid identity, suggesting a difference in allosteric regulation of the P. FALCIPARUM enzyme from its human host. A striking sequence divergence between human R2 and PfR2 at the C terminus may provide a selective target for inhibition of the malarial enzyme (Rubin ET AL.. 1993) . Transcription peaks preceding maximal DNA synthesis activity, but mRNA accumulation for the two subunits shows different temporal patterns during the cell cycle (Chakrabarti ET AL., 1993; Rubin ET AL., 1993) . Interestingly, a 20-mer antisense phosphorothioate oli gonucleotide complementary to sequences around the translational initiation codon of the small subunit show significant inhibition of growth at 1 |iM (Chakrabarti ET AL., 1993) , while a synthetic oligopeptide corres ponding to the seven C-terminal residues of PfR2 selectively inhibits malarial R2 (Rubin ET AL, 1993) . However, the former experiments must be interpreted cautiously since non-sequence specific exogenously phosphodiester or phosphothioate oligodeoxynucleotides also exert an effect on P. FALCIPARUM prolifera tion at micromolar concentration through an effect on red blood cell invasion (Clark ET AL., 1994). (Gero and O'Sullivan, 1990) . is the only localized in the mitochondrial organelles (Krungkrai, 1995) . The last two enzymes, orotate phosphoribosyltransferase (EC 2.4.2.10) and orotidylate (OMP) decarboxylase (EC 4.1.1.23), have also been
It is remarkable that the inhibition of dihydroorotase (Krungkrai, 1995) . CoQ or ubiquinones are widely distributed electron transport components that consist of a benzoquinone aromatic nucleus with four substituents. One of them is a polyprenyl tail, varying from 6 to 12 isoprene units, that confers the membrane localization through lipo philic properties; the length of this tail can be a means of characterizing different species. In mammalian cells, at the mitochondrial membrane, a large endogenous CoQ l0 pool gathers electrons from various deshydrogenases and simultaneously directs proton movements until a proton gradient is established across the mem brane which can be associated with ATP production.
In PLASMODIUM, CoQ 8 appears predominant but few studies on amounts, subcellular locations, and functions have been undertaken, and other CoQ homologues cannot be excluded. Moreover, very little is known about ubiquinone synthesis, but p-hydroxybenzoic acid could be the direct precursor of the aromatic ring, while the polyprenyl side chain of CoQ could be syn thesized via the mevalonic acid pathway. The former is important since mammalian cells have lost this biosynthetic capability, and thus rely on dietary Tyr or Phe as a source of p-hydroxybenzoic acid (Ellis, 1994) .
CoQ was subsequently recognised as a potential anti malarial target since numerous inhibitors, that are known to interfere with electron transport through the bcl complex, possess antimalarial properties. This includes menadione, menoctone, 2-cyclohexyl-3-hydroxynaptoquinone (58C80), atovaquone (566C80) and 8-aminoquinolines (antimalarial 8-aminoquinolines are proposed to be metabolized to products such as 5,6-quinoline diquinone, whose structures are similar to hydroxynaphtoquinones). Due to their structural similarities with reduced CoQ, these drugs block the respiratory chain of malarial mitochondria at complex III, inhibiting electron transfer to ubiquinone from dihydroorotate deshydrogenase.
The question of the specificity of parasite electron transport has been addressed through sequencing the 6 kb mitochondrial DNA of P. FALCIPARUM and the pre dicted structure of parasite electron transport. The overall structure of the three polypeptides, cytochrome c oxidase subunits 1 and 3, and cytochrome b (cyt b), are similar to those of other species. Cyt b is an inte gral membrane protein with 8 predicted membranespanning domains present in a multisubunit complex catalysing electron transport from CoQ to cyt c. This complex (called the bcl complex) contains 4 redox centers: 2 hemes in cyt b, one heme in cyt cl and the iron-sulfur cluster of the Rieske Fe-S protein. The two distinct catalytic sites of cyt b occur on each side of the inner mitochondrial membrane. CoQH2 oxidation occurs at the cytoplasmic site (Qo site), whereas CoQ reduction occurs at the matrix site (Qi site). Analysis of the cyt b structure in P. FALCIPARUM showed that the critical quinone binding sites were quite divergent from those of human cyt b, and that these changes likely account for the resistance of the parasite cyt bcl complex to antimycin and related inhibitors. The same features are responsible for the increased affinity of cyt b for hydroxynaphtoquinone derivatives, explaining the therapeutic value of these drugs (Vaidya ET AL., 1993). Using isolated malarial mitochondria, Fry and Pudney found that atovaquone forms a covalent adduct with a 11.5 kDa protein probably from complex III. Atova quone was able to inhibit (probably by binding at either the Qo or the Qi site) the bcl complex of mala rial parasites at 1,000-fold lower concentration than required for inhibiting rat mitochondria (Fry ET AL., 1992) . The therapeutic index is probably enhanced by the ability of mammalian cells to use exogenous pyrimidines. The moderate IN VITRO inhibition of DHOD by atovaquone (Ki = 27 (U.M) supports that inhibition of pyrimidine biosynthesis is indirect.
The inhibition of electron transfer at this site thus represents an important target for chemotherapeutic attack in parasitic protozoa. Alternative theories for the antimalarial effect involve the generation of free radi cals during interaction of the drugs with the respira tory chain (see below). However, reversion of the ato vaquone effect by orotic acid added to P. FALCIPARUM culture strongly corroborates the former mechanism (see Fowler ET AL., 1995) .
The antimalarial atovaquone is highly effective IN VITRO against erythrocytic stages with IC 50 of 1 nM, against the liver and mosquito stages, and IN VIVO against murine, simian and P. FALCIPARUM malaria. In contrast to previous members of the hydroxynaphtoquinone series, it is metabolically stable with an elimination halflife of 70 h. Despite this promising profile, its monotherapeutic use has been compromised since phase II clinical trials using 500 mg doses resulted in recru descence rates of approximately 30 %, which has been attributed to the emergence of resistant parasites. However, as an inhibitor of electron transport, it has a novel mode of action and all drug-resistant strains of P. FALCIPARUM tested to date have been sensitive to atovaquone (Hudson, 1993) . Combinations with other antimalarial daigs revealed antagonism with quinolines and artesunic acids. In contrast, combinations with tetracycline (antibiotics which are now commonly used against chloroquine-resistant strains and that interfere with mitochondrial/prokaryote-like protein synthesis (Gero & O'Sullivan, 1990) ) and proguanil were syner gistic. Proguanil was selected as the preferred partner, and this combination is now being developed by the Wellcome Foundation. Hydroxynapthoquinone also has a broad spectrum of anti-protozoal activity, and atovaquone is currently licensed as an alternative agent for oral use in the treatment of mild to moderate Pneumocystis carinii pneumonia and toxoplasmosis, opportunistic infections common in AIDS patients (Spencer et al, 1995) .
FOLATE METABOLISM
The synthesis of thymidine nucleotides is intimately linked to folate metabolism (Gero & O'Sullivan, 1990) , and pyrimidine biosynthesis can also be inhibited by folate-based inhibitors. Recent reports indicate that Plasmodium can supply its own p-aminobenzoic acid (PABA) needs through either de novo synthesis or sal vage pathways (McConkey et al, 1994) . Plasmodia also have both dihydropteroate synthetase (DHPS; EC. 2.5.1.15) and 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase (PPPK; EC 2.7.6.3) which catalyse the reaction in folic acid synthesis before DHPS. Both enzymes were recently, and concomitantly, found in gene sequence analyses to be a bifunctional protein in P. falciparum, thus corroborating their copurification (Brooks et al., 1994; Triglia et al., 1994) . The PPPK-DHPS protein is a very attractive target for anti malarial as neither of these two enzyme activities are present within the human host of the parasite, and identification and analysis of this gene are the first steps in the process of finding highly selective inhibitors. Dihydrofolate reductase (DHFR, EC 1.5.1.3) catalyses NADPH-dependent reduction of dihydrofolate (DHF) to tetrahydrofolate (THF) and exists as a bifunctional enzyme with thymidylate synthetase (TS, EC 2.1.1.45) with a 94 amino acid bridging sequence whereas TS and DHFR are separate entities in most eukaryotes. The conversion of PABA to folate is a principal target for antimalarial drugs, including potent sulfonamides which are chemical analogues of PABA and pyrime thamine and cycloguanil that inhibit the DHFR -TS, an essential enzyme for converting DHF to THF. Sulphurbased antimalarial drugs targeted at DHPS are fre quently used in synergistic combinations with DHFR inhibitors to combat chloroqLiine-resistant malaria. The molecular basis of the therapeutic activities of these compounds lies in the structural difference between malarial and mammalian DHFR, the parasite enzyme being 1,000-fold more susceptible than the mammalian counterpart to pyrimethamine and cycloguanil. The antimalarial pyrimethamine binds to dihydrofolate reductase from P. falciparum with a K diss of 10" 10 M. While the ability of malarial parasites to develop resis tance to these compounds was recognised decades ago, the molecular basis of the resistance against the drugs was only recently understood. Biochemical and genetic evidence strongly suggests that the major mechanism of DHFR-inhibitor resistance in P. falci parum is the altered binding affinity to the drugs caused by single point mutations that structurally change the enzyme (Cowman et al, 1990; Wellems, 199D. P. falciparum lines resistant to the most com monly used sulpha-drug sulfadoxine, also carry point mutations in five positions of the DHPS coding region (Brooks et al., 1994; Wang et al, 1995) , but it is not yet fully clear how this specific change affects the resis tance phenotype.
With improved knowledge of the active site of P. fal ciparum DHFR, and the specificity of point mutations involved in resistance, it would now be logical to look for alternative antifolates that could combat both resis tances. Probing the molecular structure of ligand and inhibitor binding sites may come up with some rational chemical modifications of the drugs to make them effi cient against the different mutations. The combination of these new drugs may ultimately circumvent all resis tance-conferring mutations. Physicochemical and threedimensional characterization of the DHFR-TS molecule would stimulate the development of new antifolateinhibitors. The P. falciparum DHFR enzyme has been produced using an artificial DHFR gene that possesses characteristic E. coli codons, to produce the desired amino acid sequence of the parasite DHFR. It can now be used for structural analysis and testing candidate DHFR inhibitors in vitro (Sirawaraporn et al., 1993; Sano et al., 1994) . Currently used antifolate combina tions include molecules such as sulfadoxine/pyrimethamine and sulfalene/pyrimethamine, which have long elimination half lives, of 60 and to more than 100 h. This has the advantages of allowing seric levels at efficient concentrations for long periods of time, but it also has disadvantages, e.g. adverse reactions and resistance induction. New short half-life antifolates are required to avoid the rapid appearance of resistance. Combinations using short half-life sulfonamides and sulfones, are therefore being studied. These include biguanides and triazines, the mechanisms of resistance appear to differ from those of pyrimethamine. The combination of biguanide chlorproguanil with dapsone appears to have potential for non-severe falciparum malaria (Olliaro & Trigg, 1995) .
erythrocytes, glucose uti lization is as much as 100-times the rate observed in uninfected erythrocytes. Plasmodial acristate mitochondria do not possess a functional Kreb's cycle, and lactate, which is produced from pyruvate, is the end product of glucose degradation. Most glycolytic enzymes have been observed in Plasmodium, and some of their properties differ from those of corres ponding host enzymes (Roth, 1990) . Numerous sequences have already been reported, but vulnerabi lity of the parasite to compounds that interfere with glycolysis remains to be proven. Lactate deshydrogenase represents a potential antimalarial target because of its distinctive properties as compared to human LDH, and the presence of a 5 amino acid insertion at the site that makes contact with pyruvate (Bzik ET AL., 1993).
LIPID METABOLISM
L
ipids are major constituents of biological mem branes. The lipid content of infected erythrocytes is considerably higher than that of normal ery throcytes, since it has three concentric membranes: the host cell, parasitophorous vacuole and cellular mem branes, and many membrane-bound intraparasitic orga nelles. The membrane biogenesis accompanying para site growth requires parasite-driven lipid synthesis because the erythrocyte lacks this capacity. Abundant phospholipid (PL) biosynthesis occurs during the intraerythrocytic phase, which the parasite manages through a variety of complex metabolic pathways. However, the intracellular parasite depends on the host for supplies of polar head groups and fatty acid mole cules that it cannot synthesize. As such, plasma fatty acids and lysophospholipids are both sources of fatty acids, and carrier-mediated importation of choline is increased significantly. Cholesterol does not have a structural role in malaria, and the role of exogenous lipoproteins in malaria PL production is uncertain, but lipoproteins have not been shown to be essential in this process. The parasite can synthesise phosphati dylcholine (PC) and phosphatidylethanolamine (PE) DE NOVO. It can also produce PE by decarboxylation of phosphatidylserine (PS), and PC by methylation of PE (Holz, 1977; Vial ET AL, 1990; Vial and Ancelin, 1992) . This knowledge has led to a novel antimalarial phar macological approach that involves analogues of polar head groups acting by substitution (Vial ET AL, 1984) , competition (Ancelin ET AL, 1985; Ancelin ET AL, 1986) , or with unnatural fatty acids (Beaumelle ET AL, 1988) . The most promising results were obtained with bloc kers of choline transport, probably mediated by the native (though altered) carrier of the erythrocyte mem brane. This target is easily accessible from the extra cellular space, and constitutes the rate-limiting step in the provision of choline to the parasite for PC synthesis (Ancelin ET AL, 1989) . Choline transport is effected by a diffusion system involving a cyclic and asymmetric transporter. Transacceleration experiments using imi dazole or ethanolamine showed that reorientation of the empty transporter is the rate limiting step. Like several other native carriers, its action is modified upon infection, leaving its affinity for choline identical, but increasing its maximal velocity (Vmax) 10-fold as compared to the non-perturbed carrier (Ancelin ET AL,
199D.
More than 350 compounds, synthesized by two groups of chemists, revealed that interfering with the polar head transport is lethal to the parasite. The trophozoite stage (i.e. the most intense phase of PL biosynthesis activity during the parasite cycle) was found to be by far the most sensitive stage to the drug as it had a lower IC 50 and a full antimalarial effect after 4-hour contact with the drug at low concentrations. The com pounds are also effective IN VITRO against strains or iso lates resistant to current antimalarials, highlighting their importance in the framework of multidrug resistance.
Development of the pharmacological model has now been fully validated with the malaria-infected mouse with a therapeutic index of less than 40, and success in inhibiting parasitemia by as much as 15 %. Intra muscular administration of one lead compound in AOTUS LEMURINUS monkey infected with the virulent chloroquine-resistant FVO P. FALCIPARUM isolate, suc ceeded in curing parasitemia without recrudescence, and the therapeutic index seemed to be higher than 50. As all of the most effective (nanomolar) com pounds contains quaternary amines, and as this struc tural aspect limits oral bioavailability, this structural fea ture is currently being changed without loss of biological effect, and attempts are under way to reduce toxicity and improve oral absorption. Newer com pounds possess potent antimalarial activity IN VITRO against P. FALCIPARUM (with IC 50 s in the nanomolar range), are better tolerated and far better absorbed than the former series. They also possess IN VIVO antimala rial activity in the murine model with an improved the rapeutic index. Their activity against P. FALCIPARUM in monkey has not yet been evaluated. Pharmacokinetic characteristics determined in the mouse, dog and monkey after intramuscular or oral administration revealed elimination half-lives of 7-24 h.
Hence, blocking development of the parasite using drugs which selectively interfere with PL metabolism is a quite realistic approach, and the IN VIVO antima larial activity that is exerted in monkeys without recru descence makes it very promising. Although there is no indication of potential resistance to date, a poten tial problem of using a parasite biochemical pathway as a drug target is that many parasites are able to use alternative biochemical pathways, thus conferring resis tance and rendering the drug ineffective. In terms of choline transport and inhibition of PC biosynthesis as a drug target, we noted that the alternative pathway of PC synthesis from PS does not compensate for the decrease in synthesis caused by choline transporter blockers. Nevertheless, we are aware of the fact that the role of "transporter blockers" in specifically affec ting parasite viability could be questioned, since most Digestion of up to 80 % of host cell Hb within the para sitic vacuole is associated with the release of poten tially toxic haem (Fe (II) protohaematoporphyrin) which is sequestered into an insoluble pigment called haemozoin, consisting of polymerized Fe(III) proto haematoporphyrin subunits. The haem polymerization process was previously reported to be enzymemediated and the target of the quinoline antimalarial drugs chloroquine and quinine (Slater ET AL., 1992) . It can also occur as a chemical process, dependent only on the presence of haem-derived material associated with haemozoin and not on proteins (Dorn ET AL.. 1995). However, this discovery did not invalidate haem polymerization as a target for drug intervention but the mechanism by which haemozoin formation is initiated and the mechanism of chloroquine action remains unresolved. Another possibility, among a dozen of others (Schlesinger ET AL., 1988; Pussard ET AL., 1994) , might concern the heme that accumulates during chlo roquine action, either by direct chloroquine seques tration or heme polymerase inhibition. The hemechloroquine complex might damage membranes as well as aspartic proteases or the vacuolar cysteine protease (Gluzman ETAI. 1994) . The chloroquine target has long been validated, and its identification and characterization are still problems that have to be overcome since they would allow attack of this excep tionally essential target at novel sites with new series of drugs.
NEW PERMEABILITY PATHWAYS; INTERFERENCE WITH THE HOST CELL MEMBRANE
A s the intraerythrocytic parasite matures, major modifications occur in host cell membrane: the lipid composition is altered, probably explai ning the increased fluidity; native proteins are modi fied and new proteins of parasite origin associate with it either peripherally or intrinsically; as a result of these changes, deformability of the infected cell is reduced, and the rate of PL flip-flop increases (Vial & Ancelin, 1992) . These changes have attracted much attention because of their possible involvement in the patho physiology of the disease, such as cytoadherence, rosette formation, thrombosis, anaemia and phagocy tosis, and also since they are supposed to underlie the physiological changes that permit intracellular growth of the parasite.
Investigating transport through red cell and parasite membranes has provided evidence on the permeation of low molecular weight solutes (cations and anions, amino acids and sugars) through common pathways since inhibitors of anion transport blocked entry of all of these solutes into the cells (Cabantchik, 1989) . The pathway is anion selective and non-saturable and the refore quite unlikely possess characteristics of a conventional transporters. Besides, in 1991 original studies reporting the existence of a parasite-induced parasitophorous duct (or tubovesicular system) in P. FALCIPARUM-INFECTED erythrocytes that permitted access of serum macromolecules to the parasitopho rous vacuole have met with considerable scepticism. This connecting duct that was characterized as being 70 nm diameter, would open new possibilities for novel anti-chemotherapeutic tools. However, many other experiments have found no evidence for the pas sage of material through a duct system. Details of these modified properties have been recently and compre hensively discussed in detail Elford ET AL., 1995) . Conceptually, blockage of new permea bility pathways, or use of cytotoxic agents that would only permeate erythrocytes after infection, have been formulated. This drug targeting tactic has also been experimentally demonstrated with phloridzin and its analogues (Silphen ET AL, 1988) , the zinc chelator dipicolininic acid (Ginsburg ET AL, 1986 ) that readily per meate infected erythrocytes, and also concern grami cidin inhibition of parasite growth (unpublished results and (Moll ET AL., 1991) ). Examples also include inhibi tion of choline transport and use of lipophilic iron che lators (see below). Another potential tactic would be co-administration of a cytotoxic nucleoside (tubercidine or sangivamycin) and NBPMR. This combination would inhibit entry of the cytotoxin tubercidin into normal cells, while its influx into infected cells by means of new permeability pathways would proceed unham pered. This approach assumes that all host cells are equally and efficiently protected by the transport inhi bitor against the cytotoxic nucleoside, but it disregards the potential deleterious effects of curbing adenosine detoxification. Testing this tactic IN VIVO in P. BERGHEI or P. YOELII malarias, resulted in reduction of parasi temia but not in radical cure (Gero ET AL., 1992; Gero, 1994 #606).
OXIDATIVE STRESS AS A CHEMOTHERAPEUTIC STRATEGY
A minor part of oxygen (estimated at 5 %) consumed by a human is converted by side reactions into reactive oxygen species such as O/-, HO/ ONOO' (peroxynitrite anion), HO" and H 2 0 2 . This oxydative stress is a consequence of aerobic life and is important in the organism's chemical defence against invaders. NADPH oxydase of activated leuko cytes and macrophages thus produce superoxyde anions (0 2 "~) which serve as starting material for the synthesis of chemical agents, notably the highly toxic OH* radicals that combat bacteria, parasites and tumour cells.
Erythrocytes contain high concentrations of polyunsa turated fatty acids, molecular oxygen and ferrous ions in the ligand state. It might therefore be highly vul nerable to the main potential hazards of aerobic envi ronments, i.e. formation of reactive oxidative species (ROS). Autooxydation of oxyhemoglobin (Hb) to methaemoglobin (Met-Hb) constitutes a continual spontaneous source of ROS with generation of superoxyde radicals since about 3 % of the total body Hb is converted to Met-Hb each day, even under physio logical conditions. These reactions are accelerated by high ionic strength and low pH. The Met-Hb produced is rapidly reduced again by Met-Hb reductase, which is linked, through its requirement for NADH, to the gly colytic pathway. Another source of radicals in ery- Fig 2. -Redox cycling in animal cells and malarial infected erythrocytes. 02' and H 2 0 2 are much less reactive than HO*, the former does not easily cross the biological membrane while H,0, does. Hydroxyl radical is highly reactive with a great variety of organic mole cules, but its effective diffusion is extremely low, indicating that the location of the hydroxy-radical generating system is critical; such pro duction is likely harmful within or adjacent to membranes but relatively harmless in cytoplasm. Note that H 2 0 2 produced by dismutation of 02" can react with intact Hb or MetHb, or with heme released during proteolysis, to liberate iron from the porphyrin ring. This reac tion is accelerated by low pH. Iron is required for oxygen activation to initiate lipid hydroperoxyde formation and is likely a true pro moter of hydroxyl radical generation and contributes to peroxydation in Hb-containing systems. Hb may thus act as an iron supplying agent but not as a promoter of erythrocyte lipid peroxydation per sc. These compounds are cytotoxic because of their ability to modify nucleic acids, thiol-containing proteins, and membrane lipids (Clemens & Waller, 1987; Hunt & Stacker, 1990) .
throcytes is the interaction of Hb with redox drugs or xenobiotics (Clemens ET AL., 1987; Hunt ET AL, 1990) .
PROTECTIVE MECHANISMS AGAINST OXIDATIVE
STRESS
Mechanisms for the detoxification of ROS are located in the cytoplasm and include the glutathion (GSH) peroxydase cycle and two other antioxydative enzymes, namely superoxyde dismutase (SOD; EC 1.15.1.1) and catalase (EC 1.11.1.6). Antioxidants such as vitamin C and E also protect natural molecules from oxidation or lead to the destruction of oxidised molecules. Spontaneous dismutation of superoxyde radicals is greatly accelerated by SOD. The resulting hydrogen peroxyde is eliminated by GSH peroxydase, although there is a potential reserve mechanism in the form of catalase and other GSH-dependent mechanisms. GSH peroxydase is specific to GSH as a substrate but cata lyses the decomposition of a range of peroxydes in addition to hydrogen peroxide (including oxygen, carbon, nitrogen, and sulfur based radicals). In each case, the peroxydes are reduced to alcohols. Interes tingly, GSH peroxydase deficiency appears to be enti rely benign. The tripeptide GSH is the main non-enzy matic intracellular antioxydant. It is kept in the reduced state by the flavoenzyme GSH reductase. GSH-based cellular functions include redox homeostasis, formation of deoxyribonucleotides, xenobiotic detoxification and amino acid transport. NADPH is the ultimate electron donor for decomposition of hydroperoxides by GSH and GSH reductase system. In mature erythrocytes, the only known mechanism for NADPH regeneration from NADP depends on oxidation of glucose via the hexose monophosphate shunt (HMPS). Glucose-6-phosphate deshydrogenase deficiency is typical example of here ditary sensitivity to haemolytic anaemia induced by oxi dant drugs. The presence of antioxydants in cell mem branes is a further defence against oxidation; the most important is probably vitamin E, which appears to be a critical membrane protectant by interrupting the chain reaction which would lead to further lipid peroxydation. The vitamin E radical can be reduced to vitamin E by ascorbate. Lastly, in addition to intracel lular antioxidant protection, cells and tissues are pro tected against oxidising free radicals by a complexity of extracellular antioxydant mechanisms, via e.g. com ponents capable of immobilising a metal catalyst such as iron (Clemens & Waller, 1987; Hunt & Stocker, 1990) .
REDOX PROCESS IN MALARIAL-INFECTED ERYTHROCYTES
Malarial-infected erythrocytes are demonstrably under oxidative stress (Vennerstrom ET AL., 1988; Golenser ET AL., 1989; Hunt & Stocker, 1990; Ginsburg ET AL, 1994) . Many procedures have been developed to determine enzymatic levels and oxidant stress-related metabolites in malaria-infected erythrocytes, and the scenario in P.
FALCIPARUM-INTECTED
erythrocytes seems to substantially differ from that of normal cells.
Overall, ROS could be produced in the parasite's food vacuole, due to the acidic pH, during the digestion of host cell cytosol (Atamna ET AL, 1993). In the presence of H 2 0 2 and iron which is liberated from acidified Hb (Gabay ET AL, 1994), OH radicals can be produced by a Haber-Weiss reaction. Plasmodia succeed in accu mulating ROS as attested by the increased level of metHb and lipid peroxydes (Nakornchai ET AL, 1992; Simoes ET . The parasite itself is equipped with the same antioxidant defence systems as its host cell. P. FALCIPARUM is known to contain both an adopted host cyanide-sensitive SOD and an endogenous cya nide-resistant hydrogen peroxyde-resistant SOD (Fair field Ranz ET AL, 1989) . Recent enzyme cha racterization (Becuwe ET AL, 1993) and cloning (D. Dive, personal communication) have revealed the presence of a parasite-biosynthesized, iron-dependent SOD. The cytosolic Fe-based-SOD of protozoan para sites differs both structurally and in terms of their inhi bitor profiles from cytosolic SOD of their vertebrate hosts (Fairfield ETAL, 1988; James, 1994) , and as such can be proposed as potential chemotherapeutic targets. Both P. BERGHEI and P. FALCIPARUM contain elevated levels of GSH-peroxidase. The HMPS activity of P. FAL CIPARUM infected erythrocyte is some 100-fold higher than in normal erythrocytes. Most of this activity is due to parasite HMPS, although the host cell HMPS is also activated (Atamna ET AL, 1994). Nevertheless, both host and parasite defence mechanisms may be insufficient to deal with all the ROS generated by the parasite, since infected erythrocytes display considerable lipid peroxidation and are extensively phagocytosed by a mechanism akin to that observed in oxidatively stressed erythrocytes (Turrini ET AL, 1992).
OXIDATIVE STRESS AS AN ANTIMALARIAL STRATEGY
Survival of both parasites and erythrocytes depends on the delicate balance between oxydant stress and defence mechanisms. Many pharmacologically and toxicologically active compounds exert their effects by creating an oxydative stress either by creating ROS or neutralising the antioxidant systems. In the former case, an unfavourable balance can result from enhanced sensitivity of the host cell toward oxidative stress, or because of an additional stress induced by the parasite or from external sources such as food constituents, drugs, or from the immune response. Interfering with this balance would affect successful development of the parasite. This balance is conti-nuously changing and the parasite must cope with increasing oxidant stress and the decline of its pro tective capacity.
Inherited or acquired conditions, which predispose ery throcytes to oxidative stress, offer partial protection against P. FALCIPARUM infections. Clinical and epide miological studies have provided further evidence that oxydative stress is an important mechanism for the des truction of parasites and tumour cells. The best known example is glucose-6-phosphate deshydrogenase (G6PDH) deficiency whose functional defect involves limited availability of NADPH through the hexosemonophosphate pathways, leading to an impairment of the GSH redox system, with a consequent marked increase in oxydative stress. Favism, which is charac terized by episodes of haemolytic anaemia, also afford protection against malaria, and synergizes in the pro tection with G6PDH deficiency. The antimalarial prin ciples of the fava bean that cause favism includes isouramil and divicine which act as redox cyclers (see below). Note that pro-oxidant drug administration sti mulates ROS generation, which may overwhelm pro tective mechanisms. This is particularly likely when ery throcytes defences are already defective due to hereditary enzyme deficiency. In the case of daigs such as primaquine, the dose required to produce hemo lysis of normal red cells is very much higher than that required to produce haemolysis in enzyme-deficient cells (Hunt & Stocker, 1990; Beutler, 1994; Ginsburg & Atamna, 1994; Martin, 1994) .
ANTIMALARIAL EFFECTS OF PROOXIDANTS
Compounds can directly produce ROS or produce ROS according to so-called redox cycling. The use of direct oxidants (peroxides) was proposed after the observation that numerous peroxides, including H 2 0 2 , have antimalarial properties IN VITRO (at uM concen trations) and IN VIVO. The effect is suppressed in pre sence of catalase, implicating H 2 0 2 as the causative agent. The lipophilic tert-butyl hydroperoxide which cannot be reduced by catalase, has an IC 50 of 10 uM and cures P. VINCKEI infection in mice. This agent also provokes hemolysis, which could be due to accelerated oxidative denaturation of haemoglobin, and lipid per oxidation associated with decreased GSH. Endoperoxide-containing compounds, such as epidioxy-A 7 -octalin, may also act through the production of oxidative stress (Buffinton ET AL., 1986; Vennerstrom & Eaton, 1988 Posner ET AL, 1994; Woerdenbag ET AL, 1994) .
Understanding the mechanism of action of these new antimalarials may aid in the development of better second generation drugs. They are unique molecules because they contain an endoperoxide group which is involved in their antimalarial activity, probably by producing free radicals that damage the parasite mem branes. Indeed, artemisinin produces activated oxygen species and lipid peroxydation IN VITRO (Scott ET AL, 1989) . In addition, oxydant drugs potentiate the effects of artemisinin, while antioxidants such as catalase, DTT, and oc-tocopherol antagonise artemisininmediated antimalarial action (Krungkrai ET AL, 1987) . Free radical formation is iron-dependent and iron che lators, such as DFO, inhibit artemisinin-mediated action (Kamchonwongpaisan ET AL, 1992; Meshnick ET AL, 1993) . Hemin might play a role in the antimalarial action since hemin catalyses artemisinin decomposition (Zhang ET AL, 1992; Muhia ET AL, 1994) and may interact with artemisinin to cause oxidation of protein thiols (Meshnick ET AL, 1991; Wei ET AL, 1994) . Arte misinin and derivatives possibly have a two-step mechanism of action. First, the drug interacts with intraparasitic heme, which catalyses its conversion into a free radical through opening of the drugs's endoperoxyde bridge. The free radical form of the drug then alkylates critical malarial proteins (Asawamahasakda ET AL, 1994; Meshnick, 1994; Yang ET AL, 1994) . This would explain why the drug is selectively toxic to the parasite, since the parasites are rich in heme and Parasite, 1996, 3, 3-23 heme catalyses the reductive decomposition of the endoperoxide bridge.
Several compounds X catalyse the one-electron reduc tion of 0 2 to 0 2 * through redox cycling, sometimes dependent on the presence of reducing equivalents like NAD(P)H. NADPH + 2X -» 2 X-+ NADP + + H + and 2X-+ 20 2 -> 2X + 20/ This category includes naphtoquinones, menadione, menoctone and atovaquone (already mentioned as an inhibitor of DHOD) and compounds with a catechol nucleus such as quercetin, RC-12 and gossypol, or a pyrimidine nucleus, such as divicine and isouramyl. (Vennerstrom & Eaton, 1988; Schirmer ET AL, 1995) .
GLUTATHIONE SYSTEM INHIBITORS
The main defence against ROS is the GSH redox cycle, which involves the enzymes GSH reductase and GSH peroxydase. The former catalyse GSH disulphide (GSSG, oxidised glutathion) reduction to GSH at the expense of flavonucleotide NADPH. GSH is essential for avoiding oxidant stress, and the GSH redox cycle is a major defence system for the detoxification of ROS by reacting with H 2 0 2 and organic peroxydes. The reduced GSH serves as a sulfhydryl buffer that main tains the cystein residues of Hb and other red blood cell proteins in the reduced state. The ratio of the intra cellular concentration of GSH to that of GSSG is main tained at greater than 200. GSH takes part in many bio logical functions, including detoxification of cytosolic hydrogen peroxide and organic peroxides by means of selenium-dependent GSH peroxydase (Hunt & Stacker, 1990; Ginsburg & Atamna, 1994) The G6PDH deficiency phenotype results in deficiency of NADPH, the substrate of GSH reductase in ery throcytes, and GSH is irreversibly oxidised to the disul fide, resulting in membrane damage and denaturation of Hb because of its oxidation, and this may also kill the intracellular parasite. G6PDH deficiency, which affects over 400 million people, is the most common enzymopathy in humans. The geographical correlation of its distribution with the historical endemicity of malaria suggests that the frequency of this disorder has risen through natural selection by malaria (Ruwende ET AL, 1995) . On this basis, inhibition of GSH reduc tase, represents a promising approach for malarial chemotherapy.
Human GSH reductase is one of the most thoroughly studied enzymes, including the three-dimensional staicture at 1.5 A resolution. The enzyme is a homodimer with a 52,000 Mr subunit, with two catalytic sites and amino acids of both protein subunits are involved at each catalytic site. In the reduced form, one of the two active site cysteines (cys 63) form a charge transfer with the flavin ring of FAD. The oxidised form, Eox is cha racterized by a disulphide bridge between the active site residues cys 58 and cys 63. Reduction of the disul phide with the coenzyme NADPH via the flavin ring results in the formation of dithiol Cys 58-Cys 63-This reduced enzyme EH2 interact with GSSG, leading to the release of two GSH molecules and reoxydation of the active site to complete the catalysis. The better tole rated HeCNU induces carbamoylation and alkylation of Cys 58 of GSH reductase, and has antimalarial pro perties IN VITRO and in animals. Inhibition of the enzyme does not apply to the form of the enzyme normally present IN VITRO (Eox), but only to the NADPH-reduced EH2 (Schirmer ET AL, 1995 Iron chelation treatments of malaria-parasite infected erythrocytes selectively intervenes with the iron-depen dent metabolism of malaria parasites, and have been shown to abolish plasmodial growth IN VITRO and reduce malaria infection in mice (Fritsch ET AL., 1985) , monkeys (Pollack ET AL., 1987) and in clinical cases in humans (Traore ET AL., 1991; Bunnag ET AL., 1992 , Gordeuk ET AL., 1992 , Gordeuk ET AL., 1993 . The IN VITRO antimalarial action of desferoxamine (DFO) is mani fested after 8-10 h of continuous exposure of P. FAL CIPARUM trophozoites to the drugs (Golenser ET AL., 1995) .
The antimalarial mode of action of iron chelators reside in their ability to penetrate the parasite and sequester their iron. The putative molecular target was assumed to be associated with a central iron-depen dent enzyme such as ribonucleotide reductase (see above) in analogy to the proposed mechanism of action of DFO in mammalian cells. It is also possible that DFO might destabilizes the hemozoin pigment via removal of iron, consequently releasing toxic hemederived material (Vanzyl ET AL., 1993) . For hydroxamatetype chelators, antimalarial activity has been attributed to chelation of the internal iron pool, in contrast to others that also remove iron from transferrin. Failure to recover from chelation treatment after replenishment Parasite, 1996, 3, 3-23 VIAL H. of iron to infected cells (including using ion carrier complexes), might indicate that the chelators interfere either directly or indirectly with generation or reconstitution of iron-dependent functions, but not necessa rily with iron acquisition per se. This finding is also consistent with evidence that iron chelators act not by iron removal, but rather by blocking iron integration (Lytton et al, 1994) . Intracellular iron pools affected by drugs like DFO have been localized within the para site (Loyevsky et al, 1993) , and presumably associated with Hb breakdown (Gabay & Ginsburg, 1993) .
There have been limitations on widespread clinical use of DFO due to the necessary parenteral administration to overcome slow access of the drug to infected cells and rapid washout from body fluids and, above all, frequent relapses in most malaria patients upon dis continuation of the treatment. These limitations led to development of more hydrophobic chelators which, by virtue of their membrane-penetrating character, were considered potentially useful for oral administration. Cabantchick's group improved the antimalarial efficacy of relatively safe DFO chelators by designing more hydrophobic synthetic reversed siderophores (named RSF) and N-terminal-modified DFO which fully retained the iron III binding capacity. Hydrophobic/hydrophilic balance and molecular arrangement have been controlled both by the lipophilic character of an amino acid chain emerging from the basic polyhydroxamate structure, and the length of an aliphatic chain (Cabantchik, 1995) . The antimalarial spectra of these two types of iron chelators differ in the speed of action, stage dependence and degree of reversibility of effects. While RSF had similar effects on rings and trophozoites, DFO only had major effects on trophozoites. Further more, the effects of DFO on trophozoites were relati vely slow to develop but were largely irreversible in nature, whereas those of the RSF were irreversible only on the ring stage but reversible on trophozoites. The authors proposed that these differential efficacies on the various stages reflect not only the drug's permea tion properties but also their retention within parasites after drug removal. This consideration is important since only the cytotoxic effects of drugs must be consi dered. Although DFO is not very permeant to rings, the antimalarial effect was mostly irreversible (parasite growth did not resume after drug removal), and is exclusively manifested in advanced developmental stages, since a substantial fraction of the drug taken up by cells was retained in trophozoites and schizonts even after drug removal. These modes of action also have some implications for their future as curative anti malarial agents. A combination of fast-acting sidero phores (which are able to penetrate ring-infected red cells), and slow-acting DFO derivatives (which are only permeable at the early trophozoite/schizont stages), was found to provide a new and efficient means of arresting P. falciparum growth in vitro (Golenser et al, 1995; Tsafack et al, 1995 However, the cytostatic effect could not be excluded and the differential activity is not high enough to expect specificity. In the absence of DE NOVO synthesis of cholesterol, these effects could concern other aspects of the isoprenoid pathway, such as ubiquinones pro duction .
Microtubules, a component of the skeletal system within the cell, consist of a and p" tubulin, each encoded by different but evolutionarily-related gene families, and play an important role in maintaining cell shape, cell movements, cell morphogenesis and intra cellular transport. In PLASMODIUM, microtubules are involved in stabilisation of the inner membrane of gametocytes and of their flagella. They are also pro bably essential for the spindle pole of the final mitotic division and trafficking of extranuclear vesicles in the blood stages as well as for merozoite morphogenesis and some aspects of invasion (Maessen ET AL., 1993; Bannister ET AL., 1995) . Microtubular structures contain ing a tubulin have been shown to change their confor mation during parasite replication (Read ET AL., 1993).
The P. FALCIPARUM genome contains two a tubulin genes and a single (3 tubulin gene. The y tubulin gene is also encoded by the P. FALCIPARUM genome. This protein, usually present in the cell in minor amounts, is essential for nuclear division and microtubule assembly, and present substantial differences with host proteins (Maessen ET AL., 1993)-Taxol, a plant-derived antitumor drug, has a unique mode of action, since it is a mitotic spindle poison, which binds polymerised tubulin, stoichiometrically stabilizes microtubules and inhibits their depolymerisation to free tubulin. The anti-cancer drugs taxol (Pouvelle ET AL., 1994) and taxotere both inhibit growth of P. FALCIPARUM at concen trations ranging from 1 |iM-0.1 uM. It is unclear whe ther these inhibitors act on host or parasite factors, but the former could clear parasitemia of P. CBABAUDI infected mice. However, side-effects of these anti tumor compounds restrict their use to the treatment of life-threatening diseases.
The dinitroaniline, trifluraline (at micromolar concentration) selectively binds to microtubules in malaria parasites, and disrupts their structure, inhibiting growth and differentiation of the blood stage and blocking maturation and extraflagellation of gametocytes. The drug has no or very low affinity for mammalian tubulin or microtubules, and does not affect the viability of mammalian cells (Kaidoh ET AI, 1995) . This specificity has great potential for antimalarial agents of therapeutic value. Moreover, the fact that both sexual and asexual stages of P. FALCIPARUM contain microtubular structures which play a crucial role in structural integrity, nuclear division and parasite differentiation, highlight the special interest of these targets.
In conclusion, the future of antimalarial chemotherapy is particularly cloudy in view of the spread of parasite crossresistance to drugs that are not even structurally or pharmacologically related. The first reason for this disaster is that the range of antimalarial drugs used is far too small. Only new pharmacological models will make it possible to select molecules with novel mechanisms of action, thus delaying resistance. It is also evident that all approaches are not equally promising, since the actual target is not always indispensable for PLASMODIUM, or because it is difficult to achieve the necessary therapeutic specificity. In addition, many agents only act on the intracellular parasite over a relatively short time window, thus limiting the applicability of such agents. A possible mechanism of improving the therapeutic potential is increasing their accessibility to parasites, by augmenting the drug retention by the parasite to ensure more persistent cytotoxic effects (by application of a more permeant prodrugs), or by application of a combination of drugs with different action profiles. New highly active compounds also have to satisfy a long list of criteria including bioavailability, metabolic stability, synthetic tractability, toxicity and, last but not the least, profitability. This scheme seems quite simple, but progressing sequentially through these steps is very important when developing a pharmacological model. Indeed, and unfortunately, all the criteria described must be satisfied for any approach to succeed. 
